Phase clinical trial floxuridine high-dose continuous infusion leucovorin calcium Sixty-two patients metastatic disease continuous infusion folinic acid leucovorin calcium Lv floxuridine FUDR Lv constant intravenous IV infusion days FUDR IV push days PM doses program dose-limiting toxicities diarrhea stomatitis hematologic toxicity minimal Eighty-two percent assessable patients chemotherapy regimen complete remission months partial remissions months patient population overall response rate data combination therapy Lv FUDR clinical use patient sensitivity drug combination dose FUDR initial therapy cycle days subsequent escalation patients extreme sensitivity Phase II studies progress doses 